Immunotherapy marks a paradigm shift in our approach to treating a myriad of conditions, particularly cancer. By leveraging the body's defense mechanisms, immunotherapy offers a personalized and often less invasive alternative to traditional treatments such as chemotherapy and radiation.
Central to the success of this approach is the use of advanced diagnostic tools, among which flow cytometry is pivotal. This technology is instrumental in designing and monitoring immunotherapies through cell profiling, cell sorting, functional assays, and drug screening. High-throughput screening (HTS) by flow cytometry enables the rapid analysis of a large number of cells, allowing for the identification and characterization of cellular responses.
In this panel, we will delve into the critical role of HTS, in the research and development of immunotherapies. We will highlight the value of HTS to researchers and discuss the advancements necessary to propel immunotherapies forward.
Attend this panel to:
- Understand how immunotherapy is personalized for individual patients. The challenges in customizing treatments for diverse patient populations.
- Gain insights into how patient response to immunotherapy is monitored over time.
- Explore details of how HTS cytometry identifies cellular responses, and contributes to the development and monitoring of immunotherapies.
Kevin Chen
Translation Scientist at Arcellx
Kevin Z. Chen holds a Master of Science in Cancer Biology from Emory University. As a Scientist in the Translational Sciences Department - Biomarkers and Bioanalysis Group at Arcellx, he specializes in utilizing spectral and conventional flow cytometry platforms to evaluate clinical biomarkers of patient response both pre- and post-CAR-T infusion. Kevin leads the development and validation of multiparameter flow cytometry assays, employing over 25 fluorochromes to comprehensively characterize T cell phenotype and function. He also serves as a device manager for the BD FACS Lyric and Cytek Aurora 5-laser Cytometers. Kevin's research has contributed to the understanding of T cell immunotherapy, particularly in enhancing CAR-T cell manufacturing processes.
Jonah Riddell
Product Manager at Sartorius Coporation
Jonah Riddell, PhD is a Product Manager supporting the iQue® HTS by Cytometry Platform at Sartorius Corporation. He is both an accomplished benchtop scientist and commercial leader in immunology with over 25 years of experience. Integrating a deep understanding of immunology with strategic market planning and cross-functional team leadership he is looking to innovate new products to aid in clinical and pre-clinical research. Jonah has been associated with esteemed institutions such as the Harvard Stem Cell Institute, Boston Childrens Hospital, Roswell Park Cancer Institute, Cell Signaling Technology, Advanced Instruments, Bio-Techne where his experience spans from academic to biopharma to clinical testing.
Raffaello Cimbro
Global Leader of Flow Cytometry at AstraZeneca
As the Director of Flow Cytometry at AstraZeneca, I lead a global team operating in Washington DC, Cambridge and Boston. We support the work of over 600 scientists and 150 projects each year, supporting the discovery and development of new therapies for various diseases. With an education in biotechnology and over 15 years of experience in flow cytometry, immunology, virology, and data science, I have a strong background in both human and non-human primate animal models, neuroscience, and cell therapy.